Juvenile dermatomyositis: Review and update of the pathogenesis and treatment

Revista Brasileira de Reumatologia

Volumn 50, Issue 3, 2010, Pages 305-312

  Neto, Nilton Salles Rosa ^a   Goldenstein Schainberg, Cláudia ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Autoimmune myositis; Inflammatory myopathy; Juvenile dermatomyositis; Pathogenesis; Tumor necrosis factor alpha inhibitor

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

ANAMNESIS; CAPILLAROSCOPY; CLINICAL FEATURE; DERMATOMYOSITIS; DOSE RESPONSE; DRUG WITHDRAWAL; ERYTHEMA; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; JUVENILE; JUVENILE DERMATOMYOSITIS; MUSCLE BIOPSY; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; PATHOGENESIS; PHYSICAL EXAMINATION; PROGNOSIS; PROTEIN FUNCTION; RECOMMENDED DRUG DOSE; REVIEW; VASCULAR DISEASE;

DERMATOMYOSITIS; HUMANS;

EID: 77954720077     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Compeyrot-Lacassagne S, Feldman BM. Inflammatory Myopathies in Children. Rheum Dis Clin North Am 2007;33(3):525-53.
2. Compeyrot-Lacassagne S, Feldman BM. Inflammatory Myopathies in Children Pediatr Clin North Am 2005; 52(2):493-520, vi-vii.
3. Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A et al. US Incidence of Juvenile Dermatomyositis, 1995-1998: Results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 2003; 49(3):300-5.
4. Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008; 371:2201-12.
5. Mamyrova G, O'Hanlon TP, Monroe JB, Carrick DM, Malley JD, Adams S et al. Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. Arthritis Rheum 2006; 54(12):3979-87.
6. Wedderburn LR, McHugh NJ, Chinoy H, Cooper RG, Salway F, Ollier WE et al. HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology (Oxford) 2007; 46(12):1786-91.
7. Dugan EM, Huber AM, Miller FW, Rider LG, for the International Myositis Assessment and Clinical Studies Group. Review of the classification and assessment of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatol Online J 2009; 15(2):2.
8. Fedczyna TO, Lutz J, Pachman LM. Expression of TNFα by Muscle Fibers in Biopsies from Children with Untreated Juvenile Dermatomyositis: Association with the TNFα-308A Allele. Clin Immunol 2001; 100(2):236-39.
9. Mamyrova G, ÓHanlon TP, Sillers L, Malley K, James-Newton L, Parks CG et al. Cytokine Gene Polymorphisms as Risk and Severity Factors for Juvenile Dermatomyositis. Arthritis Rheum 2008; 58(12):3941-50.
10. Pachman LM, Liotta-Davis MR, Hong DK, Kinsella TR, Mendez EP, Kinder JM et al. TNF-α 308A Allele in Juvenile Dermatomyositis: Association with Increased Production of Tumor Necrosis Factor α, Disease Duration and Pathologic Calcifications. Arthritis Rheum 2000; 43(10):2368-77.
11. Manlhiot C, Liang L, Tran D, Bitnun A, Tyrrell PN, Feldman BM. Assessment of an infectious disease history preceding juvenile dermatomyositis symptom onset. Rheumatology (Oxford) 2008; 47(4):526-9.
12. Chen YW, Shi R, Geraci N, Shrestha S, Gordish-Dressman H, Pachman LM. Duration of chronic inflammation alters gene expression in muscle from untreated girls with juvenile dermatomyositis. BMC Immunol 2008; 9:43.
13. Elst EF, Klein M, de Jager W, Kamphuis S, Wedderburn LR, van der Zee R et al. Hsp60 in inflamed muscle tissue is the target of regulatory autoreactive T cells in patients with juvenile dermatomyositis. Arthritis Rheum 2008; 58(2):547-55.
14. Li CK, Varsani H, Holton JL, Gao B, Woo P, Wedderburn LR and Juvenile Dermatomyositis Research Group (UK and Ireland). MHC Class I overexpression on muscles in early juvenile dermatomyositis. J Rheumatol 2004; 31(3):605-9.
15. Gonçalves FG, Chimelli L, Sallum AM, Marie SK, Kiss MH, Ferriani VP. Immunohistological analysis of CD59 and membrane attack complex of complement in muscle in juvenile dermatomyositis. J Rheumatol 2002; 29(6):1301-7.
16. Zhao Y, Fedczyna TO, McVicker V, Caliendo J, Li H, Pachman LM. Apoptosis in the skeletal muscle of untreated children with juvenile dermatomyositis: impact of duration of untreated disease. Clin Immunol 2007; 125(2):165-72.
17. Sallum AM, Marie SK, Wakamatsu A, Sachetti S, Vianna MA, Silva CA et al. Immunohistochemical analysis of adhesion molecule expression on muscle biopsy specimens from patients with juvenile dermatomyositis. J Rheumatol 2004; 31(4):801-7.
18. Jain A, Shama MC, Sarkar C, Bhatia R, Singh S, Handa R. Major Histocompatibility Complex Class I and II Detection as a Diagnostic Tool in Idiopathic Inflammatory Myopathies. Arch Pathol Lab Med 2007; 131:1070-6.
19. Niewold TB, Kariuki SN, Morgan GA, Shrestha S, Pachman LM. Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. Arthritis Rheum 2009; 60(6):1815-24.
20. Uzel G, Pachman LM. Cytokines in juvenile dermatomyositis pathophysiology: potential and challenge. Curr Opin Rheumatol 2003; 15:691-97.
21. de Padilla CML, Reed AM. Dendritic cells and the immunopathogenesis of idiopathic inflammatory myopathies. Curr Opin Rheumatol 2008; 20:669-74.
22. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292(7):344-7.
23. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292(8):403-7.
24. Christen-Zaech S, Seshadri R, Sundberg J, Paller AS, Pachman LM. Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis. Arthritis Rheum 2008; 58(2):571-6.
25. Pilkington C. Clinical assessment in juvenile idiopathic inflammatory myopathies and the development of disease activity and damage tools. Curr Opin Rheumatol 2004; 16:673-7.
26. Scott DL, Kingsley GH. Use of imaging to assess patients with muscle disease. Curr Opin Rheumatol 2004; 16:678-83.
27. Rouster-Stevens KA, Langman CB, Price HE, Seshadri R, Shore RM, Abbott K et al. RANKL: osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis. Arthritis Rheum 2007; 56(3):977-83.
28. Santmyire-Rosenberger B, Dugan EM. Skin involvement in dermatomyositis. Curr Opin Rheumatol 2003; 15:714-22.
29. Pachman LM. Juvenile dermatomyositis: immunogenetics, pathophysiology, and disease expression. Rheum Dis Clin North Am 2002; 28(3):579-602,vii.
30. Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A et al. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore) 2008; 87(2):70-86.
31. Gunawardena H, Wedderburn LR, Chinoy H, Betteridge ZE, North J, Ollier WE et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 2009; 60(6):1807-14.
32. Gunawardena H, Wedderburn LR, North J, Betteridge Z, Dunphy J, Chinoy H et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) 2008; 47(3):324-8.
33. Pereira RM, Lerner S, Maeda WT, Goldenstein-Schainberg C, Cossermelli W. Pericardial tamponade in juvenile dermatomyositis. Clin Cardiol 1992; 15(4):301-03.
34. Likert R. A technique for the measurement of attitudes. Archives of Psychology 1932; 22(140):1-55.
35. Lovell DJ, Lindsley CB, Rennebohm RM, Ballinger SH, Bowyer SL, Giannini EH et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): A Quantitative Tool for the Evaluation of Muscle Function. Arthritis Rheum 1999; 42(10):2213-9.
36. Rennebohm RM, Jones K, Huber AM, Ballinger SH, Bowyer SL, Feldman BM et al. Normal Scores for Nine Maneuvers of the Childhood Myositis Assessment Scale. Arthritis Rheum 2004; 51(3):365-70.
37. Huber AM, Feldman BM, Rennebohm RM, Hicks JE, Lindsley CB, Perez MD et al. Validation and Clinical Significance of the Childhood Myositis Assessment Scale for Assessment of Muscle Function in the Juvenile Idiopathic Inflammatory Myopathies. Arthritis Rheum 2004; 50(5):1595-603.
38. Moorthy LN, Peterson MG, Harrison MJ, Onel KB, Lehman TJ. Physical function assessment tools in pediatric rheumatology. Pediatr Rheumatol Online J 2008; 6:9.
39. Machado CS, Ruperto N, Silva CH, Ferriani VP, Roscoe I, Campos LM et al. The Brazilian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001; 19(4 Suppl 23):S25-29.
40. Bode RK, Klein-Gitelman MS, Lechman TS, Pachman LM. Disease Activity Score for Children with Juvenile Dermatomyositis: Reliability and Validity Evidence. Arthritis Rheum 2003; 49(1):7-15.
41. Ruperto N, Ravelli A, Murray KJ, Lovell DJ, Andersson-Gare B, Feldman BM et al. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology 2003; 42:1452-9.
42. Apaz MT, Saad-Magalhães C, Pistorio A, Ravelli A, de Oliveira Sato J, Marcantoni MB et al. Health-related quality of life of patients with juvenile dermatomyositis: results from the Pediatric Rheumatology International Trials Organisation multinational quality of life cohort study. Arthritis Rheum 2009; 61(4):509-17.
43. Huber AM, Dugan EM, Lachenbruch PA, Feldman BM, Perez MD, Zemel LS et al. The Cutaneous Assessment Tool (CAT): Development and Reliability in Juvenile Idiopathic Inflammatory Myopathy. Rheumatology (Oxford) 2007; 46(10):1606-11.
44. Huber AM, Lachenbruch PA, Dugan EM, Miller FW, Rider LG and Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Alternative Scoring of the Cutaneous Assessment Tool (CAT) in Juvenile Dermatomyositis: Results Using an Abbreviated Format. Arthritis Rheum 2008; 59(3):352-6.
45. Klein RQ, Bangsert CA, Costner M, Connolly MK, Tanikawa A, Okawa J et al. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br J Dermatol 2008; 159:887-94.
46. Huber AM, Dugan EM, Lachenbruch PA, Feldman BM, Perez MD, Zemel LS et al. Preliminary Validation and Clinical Meaning of the Cutaneous Assessment Tool in Juvenile Dermatomyositis. Arthritis Rheum 2008; 59(2):214-21.
47. Ruperto N, Ravelli A, Pistorio A, Ferriani V, Calvo I, Ganser G et al. The Provisional Paediatric Rheumatology International Trials Organization/American College of Rheumatology/European League Against Rheumatism Disease Activity Core Set for the Evaluation of Response to Therapy in Juvenile Dermatomyositis: A Prospective Validation Study. Arthritis Rheum 2008; 58(1):4-13.
48. Pachman LM, Abbott K, Sinacore JM, Amoruso L, Dyer A, Lipton R et al. Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr 2006; 148:247-53.
49. Rouster-Stevens KA, Gursahaney A, Ngai KL, Daru JA, Pachman LM. Pharmacokinetic Study of Oral Prednisolone Compared with Intravenous Methylprednisolone in Patients with Juvenile Dermatomyositis. Arthritis Rheum 2008; 59(2):222-6.
50. Kim S, El-Hallak M, Dedeoglu F, Zurakowski D, Fuhlbrigge RC, Sundel RP. Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. Arthritis Rheum 2009; 60(6):1825-30.
51. Stringer E, Feldman BM. Advances in the treatment of juvenile dermatomyositis. Curr Opin Rheumatol 2006; 18:503-6.
52. Riley P, Maillard SM, Wedderburn LR, Woo P, Murray KJ, Pilkington CA. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology 2004; 43:491-6.
53. Hassan J, van der Net JJ, van Royen-Kerkhof A. Treatment of refractory juvenile dermatomyositis with tacrolimus. Clin Rheumatol 2008; 27(11):1469-71.
54. Amano H, Nagai Y, Katada K, Hashimoto C, Ishikawa O. Successful treatment of cutaneous lesions in juvenile dermatomyositis with high-dose intravenous immunoglobulin. Br J Dermatol 2007; 156(6):1390-2.
55. Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 2008; 47(6):877-80.
56. de Oliveira SK, de Almeida RG, Fonseca AR, Rodrigues MC, Sztajnbok F, Diniz C. Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center. Acta Reumatol Port 2007; 32(2):139-50.
57. Cooper MA, Willingham DL, Brown DE, French AR, Shih FF, White AJ. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 2007; 56(9):3107-11.
58. Takken T, van der Net J, Engelbert RH, Pater S, Helders PJ. Responsiveness of exercise parameters in children with inflammatory myositis. Arthritis Rheum 2008; 59(1):59-64.
59. Harris-Love MO. Physical activity and disablement in the idiopathic inflammatory myopathies. Curr Opin Rheumatol 2003; 15:679-90.
60. Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000; 43(3):541-9.
61. Stringer E, Singh-Grewal D, Feldman BM. Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. Arthritis Rheum 2008; 58(11):3585-92.
62. Stringer E, Singh-Grewal D, Feldman BM. Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features Erratum in: Arthritis Rheum 2008; 58(12):3950.
63. Gunawardena H, Betteridge ZE, McHugh NJ. Newly identified autoantibodies: relationship to idiopathic inflammatory myopathy subsets and pathogenesis. Curr Opin Rheumatol 2008; 20(6):675-80.